Search Results
Jun 02, 2025, 13:37 ET Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
profile throughout the dose-escalation phase, with no dose-limiting toxicities (DLTs) reported. Cytokine release syndrome (CRS) occurred in 24 patients (69%), primarily Grade 1, with only four patients experiencing Grade 2 events. CRS was mostly limited to the first administration of ISB 2001, and no severe or life-threatening
More news about: Ichnos Glenmark Innovation
Jun 02, 2025, 08:04 ET IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Release Syndrome (CRS): IMDELLTRA® can cause CRS including serious or life-threatening reactions. In the pooled safety population, CRS occurred in 55% of patients who received IMDELLTRA®, including 34% Grade 1, 19% Grade 2, 1.1% Grade 3 and 0.5% Grade 4. Recurrent CRS occurred in
More news about: Amgen
Jun 01, 2025, 08:10 ET Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune
More news about: Johnson & Johnson
May 28, 2025, 07:22 ET IBS Software to provide Air France-KLM Group with solutions to optimise flight operations and reduce the impact of delays
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
May 27, 2025, 12:06 ET Research Payloads to Support Long-Duration Spaceflight and Improve Osteoarthritis and Cancer Treatment Return From Space Station
NASA's SpaceX CRS-32 About the International Space Station (ISS) National Laboratory:The International Space Station (ISS) is a one-of-a-kind
More news about: International Space Station National Lab
May 26, 2025, 11:00 ET SeekInCare: New Multi-Omics Blood Test Shows Promise for Early Cancer Detection Across Multiple Cancer Types
incorporating genomic and epigenetic alterations in conjunction with clinically validated protein biomarkers. Equipped with proprietary AI- and big data-driven CRS algorithm, SeekInCare exhibits superior effectiveness to detect dozens of cancer types at high specificity. SeekInCare is intended for use in individuals
More news about: SeekIn Inc
May 23, 2025, 11:10 ET PeproMene Bio, Inc. und das Institute for Follicular Lymphoma Innovation (IFLI) geben bekannt, dass der erste Patient mit follikulärem Lymphom (FL), der mit BAFF-R zielgerichteten CAR-T-Zellen (PMB-CT01) behandelt wurde, ein vollständiges Ansprechen erreicht hat
einschließlich MCL, DLBCL und FL, die mit PMB-CT01 behandelt wurden, haben eine anhaltende CR (1 bis mehr als 29 Monate) erreicht, wobei ausschließlich Grad 1 CRS und ICANS beobachtet wurden.IRVINE, Kalifornien, 23. Mai 2025
More news about: PeproMene Bio, Inc.
May 23, 2025, 00:12 ET 페프로민 바이오•여포성 림프종 혁신 연구소(IFLI), BAFF 표적으로 하는 CAR-T 세포 치료제(PMB-CT01)로 치료받은 첫 번째 여포성 림프종(FL) 환자의 완전 관해 달성 발표
1개월 만에 완전 관해 달성PMB-CT01로 치료받은 재발/불응성 B-세포 비호지킨림프종(B-NHL) 환자 7명 전원(MCL, DLBCL, FL 포함) 지속적 완전 관해(1~29개월 이상)를 달성했으며, 모든 환자에게서 CRS 및 ICANS은 모두 가장 경미한 1등급 수준으로만 관찰돼어바인, 캘리포니아주, 2025년 5월 23일 /PRNewswire/
More news about: PeproMene Bio, Inc.
May 22, 2025, 20:00 ET CARsgen's Satri-cel Abstract Available on ASCO Website
patients. Furthermore, satri-cel demonstrated a favorable overall safety profile. Only 4 cases of Grade 3 cytokine release syndrome (CRS) were reported, and no Grade 4-5 CRS events were observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported. This is the first confirmatory
More news about: CARsgen Therapeutics
May 22, 2025, 17:00 ET Novita Highlights Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at 2025 ASCO Annual Meeting
metastases.Notable outcomes include continued CR in a cervical cancer patient, target lesion CR in an endometrial cancer patient, pathological CRs in a pancreatic cancer patient and a patient with gastroesophageal junction adenocarcinoma, clinical CR in a cutaneous squamous cell carcinoma patient,
More news about: Novita Pharmaceuticals, Inc.
May 22, 2025, 16:15 ET AbelZeta Presents New Data on C-CAR168 for the Treatment of Autoimmune Diseases at LUPUS 2025
28, 2025;Early clinical data showed that C-CAR168 was well tolerated. Four LN patients and one SPMS patient experienced low-grade 1-2 CRS with median time to onset of 2 days post C-CAR168 treatment. Neither ICANS nor severe infection was observed.Mechanism of Action and
More news about: AbelZeta Pharma, Inc.
May 20, 2025, 10:22 ET PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response
Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with PMB-CT01 have achieved a sustained CR (1 to 29+ months) with strictly grade 1 CRS and ICANS observed.IRVINE, Calif.,
More news about: PeproMene Bio, Inc.
May 20, 2025, 10:22 ET PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response
Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with PMB-CT01 have achieved a sustained CR (1 to 29+ months) with strictly grade 1 CRS and ICANS observed.IRVINE, Calif.,
More news about: PeproMene Bio, Inc.
May 14, 2025, 08:00 ET ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
Four of the efficacy evaluable patients (2 each at 120µg/kg and 150 µg/kg) converted to CR within 3 weeks after the data cutoff and are included as CRs. Twenty of 21 responders have remained in response and the median duration of response has not been reached. Manageable safety and tolerability were
More news about: ADC Therapeutics SA
May 14, 2025, 07:45 ET ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
Four of these patients (2 each at 120µg/kg and 150 µg/kg) converted to complete response (CR) within 3 weeks after the data cutoff and are included as CRs. Updated data will be presented during EHA2025. Key highlights in the LOTIS-7 abstract are as follows: In
More news about: ADC Therapeutics SA
May 13, 2025, 08:00 ET Dominari Holding's Strategic Interest in Bitcoin Mining Set to Go Public
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
May 13, 2025, 06:00 ET Strategic Partnership | Sanyou Bio and TransRecoBio Forge Strategic Alliance to Build a New Ecosystem for the Full Industry Chain
innovative biologic drugs. Sanyou has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make the R&D easy for innovative biologics". Sanyou has established an integrated innovative biologic drug
More news about: Sanyou Bio
May 11, 2025, 20:00 ET CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
findings from up to four months of follow-up include: No dose-limiting toxicities (DLTs), ≥Grade 3 cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GVHD) were reported. The product demonstrated a favorable
More news about: CARsgen Therapeutics
May 07, 2025, 21:00 ET SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
was observed in 94% of patients and resolved within 14 days. Other common treatment-related adverse events (TRAEs) included cytokine release syndrome (CRS), neutropenia, and thrombocytopenia—all of which were manageable and reversible. Prof. Dr. Shunda Du, Chief of
More news about: SCG Cell Therapy Pte Ltd
May 06, 2025, 11:33 ET NSSA's Moorman Center for Space Studies Occasional Paper Release: Reconciliation and National Security Space
Questions", March 6, 2025https://www.congress.gov/crs-product/R484442https://armedservices.house.gov/uploadedfiles/bill_text.pdf
More news about: National Security Space Association
May 06, 2025, 08:45 ET Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy - Iomab-ACT has the potential to increase the addressable market
More news about: Actinium Pharmaceuticals, Inc.
Apr 30, 2025, 03:11 ET Genocury Biotech Announces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Unlike conventional CAR-T, which carries a ~50% risk of cytokine release syndrome (CRS) and neurotoxicity, this novel therapeutic approach demonstrated complete absence of: Cytokine release syndrome (CRS) Immune effector cell-associated neurotoxicity syndrome (ICANS)
More news about: Genocury Biotech
Apr 30, 2025, 01:00 ET Tata Tea JaagoRe's AI campaign champions the power of collective actions for a positive climate impact
households, giving it an unparalleled ability to leverage the Tata brand in consumer products. The Company has a consolidated annual turnover of ~Rs. 15,206 Crs with operations in India and International markets. For more information, please visit
More news about: Tata Consumer Products Limited
Apr 25, 2025, 20:30 ET Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality
Presentations:ATG-201 (CD19 x CD3 T cell engager)Title: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseasesAbstract Number: 7326Session Category: ImmunologySession
More news about: Antengene Corporation Limited
Apr 25, 2025, 08:24 ET CHOICE HOTELS INTERNATIONAL FÜHRT MEWS CLOUD TECHNOLOGIE ALS NEUSTE OPTION DES PROPERTY MANAGEMENT SYSTEMS FÜR INTERNATIONALE FRANCHISENEHMER EIN
Download von Geschenkkarten per App anbot.2018 brachte Choice choiceEDGE auf den Markt, das erste cloudbasierte zentrale Reservierungssystem (CRS) der Branche.Im Jahr 2019 wurde Choice das erste Hotelunternehmen, welches sich verpflichtet, zu 100 % auf AWS
More news about: Mews